Q-omics provides the consensus-scored WDR81 profile across patient tissues and cancer cell-line models. WDR81 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, WDR81 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, WDR81 protein abundance shows 22,396 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where WDR81 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WDR81 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WDR81 survival associations across molecular data types. WDR81 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (10) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WDR81 RNA expression–survival associations across cancer types. High WDR81 expression shows unfavorable associations in LUSC, but favorable associations in HNSC, SCLC, KIRC, ESCA and UCEC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for WDR81 RNA expression.
This table summarizes WDR81 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for WDR81. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WDR81 shows lower tumor expression in BRCA and higher tumor expression in KIRC, HNSC, STAD, LIHC and CHOL. The KIRC box plot shows higher WDR81 RNA expression in tumor versus normal tissue (log2 FC = +1.343, t-test p < 0.001).
This table shows molecular features associated with WDR81 in patient tissues and cancer cell lines. In patient samples, WDR81 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, WDR81 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and LARGE_INTESTINE.
